5 results about "Human papillomavirus types" patented technology

This invention provides a non-classical crRNA, reagent, kit, and application for one-step RPA-Cas12a nucleic acid detection. Based on classic crRNA, the non-classical crRNA shortens the 5' end by two bases and / or adjusts the stem-loop base structure to one of UCUUUU, UCUUU, UGUUU, UGUU, or UAAGU. This non-classical crRNA structure reduces the affinity of the Cas12a-crRNA complex for the target DNA, weakens the cis-cleavage activity of Cas12a, and increases the trans-cleavage activity of Cas12a, without requiring additional base modifications. This invention achieves a detection limit of 1 fM in the detection of Group B Streptococcus and Human Papillomavirus 16, with a sensitivity approximately 10-fold higher than before optimization.

The invention discloses a bigeminy immunoassay kit for detecting an HPV (human papillomavirus) antibody and a preparation method of the bigeminy immunoassay kit, relates to the field of biomedicine, and is characterized in that the bigeminy immunoassay kit for detecting the HPV antibody and the preparation method of the bigeminy immunoassay kit are provided. The magnetic microspheres for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 are coated with an HPV16 antibody and an HPV18 antigen, acridinium ester is used for marking the HPV16 antigen and the HPV18 antibody, an in-vitro diagnostic kit for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 is established on the basis, and a chemiluminescence immunoassay method is combined for analysis. The bigeminy immunoassay kit for quantitative detection of the HPV antibody is high in sensitivity, good in specificity, simple and convenient to operate and appropriate in price.

Disclosed are methods of selectively expanding a number of T cells each having antigenic specificity for a human papillomavirus (HPV) 6 or 11 antigen expressed by a tissue of a mammal. Also disclosed are methods of preparing a T cell product from an HPV 6 or 11 antigen positive papilloma from a mammal. Methods of treating or preventing a condition caused by a chronic HPV 6 or 11 infection in a mammal are also disclosed.

This invention discloses a germplasm screening and identification kit for anthracnose-resistant Camellia oleifera and its application, belonging to the technical field of germplasm screening and identification of anthracnose resistance genes in Camellia oleifera. Based on eight anthracnose resistance genes in Camellia oleifera, this invention develops a germplasm screening and identification kit for anthracnose-resistant Camellia oleifera. This invention enables rapid and efficient identification of anthracnose-resistant Camellia oleifera germplasm and can be used for high-throughput screening of anthracnose-resistant Camellia oleifera lines, providing a new method for disease-resistant breeding of Camellia oleifera.

The invention relates to the field of therapeutic nucleic acid vaccines, and discloses a design strategy of a therapeutic mRNA vaccine applicable to various human papilloma virus (HPV) type infection related precancerous lesions and tumors. The mRNA sequentially encodes E6 and E7 antigens from the N terminal to the C terminal, wherein the E6 and E7 antigens comprise a membrane-directed peptide and HPV de-carcinogenic antigens, and the E6 and E7 antigens can be directly connected or connected through a flexible joint of 1-20 amino acids. The mRNA can be delivered by various delivery systems, and the vaccine induces potent and lasting cellular immunity and humoral immunity in a mouse model; the strategy is suitable for treatment of high-grade squamous intraepithelial lesions and malignant tumors at the positions of cervix uteri, vagina, anus and the like caused by various HPV high-risk infections.